Table 1.
Demographics and clinical characteristics by histologic subtype
| Adenocarcinoma (AC) | Adenosquamous carcinoma (A‐SCC) | Squamous cell carcinoma (SCC) | Total: 94 928 | |
|---|---|---|---|---|
| N = 94 016 | N = 757 | N = 155 | ||
| N (%) | N (%) | N (%) | P (for AC vs SCC) | |
| Age | ||||
| ≤50 | 6951 (7.0) | 56 (7.0) | 11 (7.0) | .89 |
| >50 | 87 065 (93.0) | 701 (93.0) | 144 (93.0) | |
| Sex | ||||
| Male | 46 280 (49.2) | 381 (50.3) | 79 (51.0) | .67 |
| Female | 47 736 (50.8) | 376 (49.7) | 76 (49.0) | |
| Charlson comorbidity score | ||||
| 0 | 64 984 (69.1) | 518 (68.4) | 101 (65.2) | .55 |
| 1 | 22 708 (24.2) | 186 (25.6) | 43 (27.7) | |
| 2+ | 6324 (6.7) | 53 (7.0) | 11 (7.1) | |
| Tumor location | ||||
| Head | 63 736 (67.8) | 385 (50.9) | 75 (48.4) | <.001 |
| Body | 9428 (10.0) | 97 (12.8) | 34 (21.9) | |
| Tail | 6035 (6.4) | 162 (21.4) | 20 (12.9) | |
| Pancreatic duct | 644 (0.7) | 4 (0.5) | 0 (0.0) | |
| Other | 14 173 (15.1) | 109 (14.4) | 26 (16.8) | |
| Tumor grade | ||||
| Low | 31 404 (62.5) | 190 (33.7) | 18 (21.7) | <.001 |
| High | 18 807 (37.5) | 374 (66.3) | 65 (78.3) | |
| LVSI | ||||
| Negative | 11 452 (12.2) | 126 (16.6) | 15 (9.7) | .02 |
| Positive | 8559 (9.1) | 142 (18.8) | 5 (3.2) | |
| Unknown | 74 005 (78.7) | 489 (64.6) | 135 (87.1) | |
| CA 19‐9 (U/mL) | ||||
| ≤35 | 8860 (9.4) | 87 (11.5) | 18 (11.6) | .15 |
| 35‐90 | 8341 (8.9) | 75 (9.9) | 18 (11.6) | |
| >90 | 15 631 (16.6) | 111 (14.7) | 19 (12.3) | |
| Unknown | 61 184 (65.1) | 484 (63.9) | 100 (64.5) | |
| Clinical T‐stage | ||||
| cT0 | 160 (0.2) | 2 (0.4) | 0 (0.0) | .15 |
| cT1 | 5896 (8.4) | 24 (4.3) | 7 (5.7) | |
| cT2 | 17 414 (24.8) | 168 (30.3) | 21 (17.1) | |
| cT3 | 27 424 (39.0) | 253 (45.8) | 53 (43.1) | |
| cT4 | 19 392 (27.6) | 106 (19.2) | 42 (34.2) | |
| Clinical N‐stage | ||||
| cN0 | 47 654 (68.8) | 373 (69.2) | 74 (66.1) | .38 |
| cN1 | 21 621 (31.2) | 166 (30.8) | 38 (33.9) | |
| Clinical stage group | ||||
| I | 17 966 (26.4) | 154 (28.9) | 20 (17.1) | .03 |
| II | 30 820 (45.3) | 271 (50.8) | 53 (45.3) | |
| III | 19 304 (28.4) | 108 (20.3) | 44 (37.6) | |
| Resectability | ||||
| Resectable/borderline resectable | 72 042 (79.9) | 641 (85.9) | 109 (75.7) | .11 |
| Unresectable | 18 120 (20.1) | 105 (14.1) | 37 (25.3) | |
| Pathologic T‐stage | ||||
| pT0 | 159 (0.4) | 3 (0.5) | 1 (2.9) | .03 |
| pT1 | 3272 (7.8) | 7 (1.3) | 2 (5.9) | |
| pT2 | 7239 (17.1) | 103 (18.7) | 8 (23.5) | |
| pT3 | 29 082 (68.9) | 406 (73.6) | 18 (52.9) | |
| pT4 | 2468 (5.8) | 33 (6.0) | 5 (14.7) | |
| pTis | 8 (0.0) | 0 (0.0) | 0 (0.0) | |
| Pathologic N‐stage | ||||
| pN0 | 16 209 (38.7) | 227 (42.0) | 16 (51.6) | .14 |
| pN1 | 25 665 (61.3) | 314 (58.0) | 15 (49.4) | |
| Margin status | ||||
| Negative | 31 584 (84.0) | 431 (86.7) | 26 (81.3) | .68 |
| Positive | 6028 (16.0) | 66 (13.3) | 6 (18.8) | |
Data presented as N (%) unless otherwise noted. P values given by Pearson's chi‐squared and two‐sided t tests for categorical and continuous variables, respectively. Low‐grade category included well‐differentiated and moderately differentiated tumors; high‐grade category included poorly differentiated tumors.
The bolded values are statistically significant to P < .05.
Abbreviations: LVSI indicates lymphovascular space invasion; N, numbers; N‐stage, clinical nodal stage as per American Joint Committee on Cancer 7th Edition; T‐stage, clinical tumor stage as per American Joint Committee on Cancer 7th Edition.